1Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, Korea
2Research Institute of Clinical Medicine of Chonbuk National University, Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Korea
3Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea
4Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea
5Department of Internal Medicine, Wonkwang University School of Medicine, Iksan, Korea
6Department of Internal Medicine, Soonchunhyang University Hospital, Cheonan, Korea
7Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea
8Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea
9Center for Clinical Pharmacology and Biomedical Research Institute, Chonbuk National University Hospital, Jeonju, Korea
Copyright © 2019 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors thank all of the researchers and the participating heath centers including CJ Health Care for the kind donation of study drugs.
Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study
Characteristic | Olanzapine (n=29) | Placebo (n=25) |
---|---|---|
Sex | ||
Male | 23 (79) | 22 (88) |
Female | 6 (21) | 3 (12) |
Age (yr) | ||
Median | 60 | 63 |
Range | 30-76 | 42-79 |
ECOG performance status | ||
0 | 6 (21) | 3 (12) |
1 | 23 (79) | 22 (88) |
Chemotherapy regimen | ||
Oxaliplatin containing | 16 (55) | 14 (56) |
Irinotecan containing | 11 (38) | 9 (36) |
Carboplatin containing | 2 (7) | 2 (8) |
Purpose of chemotherapy | ||
Palliative | 16 (55) | 18 (72) |
Adjuvant | 13 (45) | 6 (24) |
Neoadjuvant | 0 | 1 (4) |
Primary site of disease | ||
Colorectal | 18 (62) | 13 (52) |
Stomach | 8 (28) | 7 (28) |
Lung | 2 (7) | 2 (8) |
Other | 1 (3) | 3 (12) |
Previous alcohol consumption | ||
Yes | 13 (45) | 5 (20) |
No | 16 (55) | 20 (80) |
Variable | Olanzapine (n=29) | Placebo (n=25) | Total (n=54) | p-value |
---|---|---|---|---|
0-24 Hours after chemotherapy | ||||
No | 1 (3.5) | 3 (12.0) | 4 (7.4) | 0.326 |
Yes | 28 (96.5) | 22 (88.0) | 50 (92.6) | |
24-120 Hours after chemotherapy | ||||
No | 9 (31.0) | 13 (52.0) | 22 (40.7) | 0.118 |
Yes | 20 (69.0) | 12 (48.0) | 32 (59.3) | |
0-120 Hours after chemotherapy | ||||
No | 9 (31.0) | 13 (52.0) | 22 (40.7) | 0.118 |
Yes | 20 (69.0) | 12 (48.0) | 32 (59.3) |
Variable | Olanzapine (n=29) | Placebo (n=25) | Total (n=54) | p-value |
---|---|---|---|---|
Vomiting in the overall phase | ||||
No | 20 (69.0) | 14 (56.0) | 34 (63.0) | 0.325 |
Yes | 9 (31.0) | 11 (44.0) | 20 (37.0) | |
Significant vomiting in the overall phase | ||||
No | 24 (82.8) | 14 (56.0) | 38 (70.4) | 0.032 |
Yes | 5 (17.2) | 11 (44.0) | 16 (29.6) | |
Frequency of rescue medication | 0.03±0.19 | 1.88±2.88 | 0.002 | |
Time to the use of rescue medication (hr) | 2.55±13.74 | 19.44±28.23 | 0.004 |
Variable | Olanzapine (n=29) | Placebo (n=25) | p-value |
---|---|---|---|
FLI-E total score | |||
Mean±SD | 119.12±15.49 | 107.81±22.27 | 0.009 |
Median (min-max) | 125.98 (64.97-125.98) | 120.22 (40.50-125.98) | |
Nausea domain | |||
Mean±SD | 58.48±9.95 | 50.56±13.64 | 0.004 |
Median (min-max) | 62.99 (17.52-62.99) | 57.23 (17.04-62.99) | |
Vomiting domain | |||
Mean±SD | 60.64±7.06 | 57.25±10.68 | 0.078 |
Median (min-max) | 62.99 (28.14-62.99) | 62.93 (23.46-62.99) | |
Impact on daily life, n (%) | |||
No | 26 (89.7) | 15 (60.0) | 0.015 |
Yes | 3 (10.3) | 10 (40.0) |
Values are presented as number (%). ECOG, European Cooperative Oncology Group.
Values are presented as number (%).
Values are presented as number (%) or mean±standard deviation.
CINV, chemotherapy-induced nausea and vomiting; FLI-E, the Functional Living Index-Emesis; SD, standard deviation.